These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21317599)

  • 1. The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation.
    Schackman BR; Leff JA; Botsko M; Fiellin DA; Altice FL; Korthuis PT; Sohler N; Weiss L; Egan JE; Netherland J; Gass J; Finkelstein R;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S76-82. PubMed ID: 21317599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.
    Weiss L; Netherland J; Egan JE; Flanigan TP; Fiellin DA; Finkelstein R; Altice FL;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S68-75. PubMed ID: 21317597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.
    Korthuis PT; King C; Cook RR; Khuyen TT; Kunkel LE; Bart G; Nguyen T; Thuy DT; Bielavitz S; Nguyen DB; Tam NTM; Giang LM
    Lancet HIV; 2021 Feb; 8(2):e67-e76. PubMed ID: 33539760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.
    Chaudhry AA; Botsko M; Weiss L; Egan JE; Mitty J; Estrada B; Lucas GM; Woodson T; Flanigan TP; Fiellin DA;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S14-21. PubMed ID: 21317589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Policy implications of integrating buprenorphine/naloxone treatment and HIV care.
    Finkelstein R; Netherland J; Sylla L; Gourevitch MN; Cajina A; Cheever L;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S98-S104. PubMed ID: 21317602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment.
    Weiss L; Egan JE; Botsko M; Netherland J; Fiellin DA; Finkelstein R
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S7-13. PubMed ID: 21317598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone.
    Sullivan LE; Botsko M; Cunningham CO; O'Connor PG; Hersh D; Mitty J; Lum PJ; Schottenfeld RS; Fiellin DA;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S54-61. PubMed ID: 21317595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care.
    Schackman BR; Merrill JO; McCarty D; Levi J; Lubinski C
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S247-53. PubMed ID: 17109311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of buprenorphine for substance-abuse treatment by HIV care providers.
    Friedland G; Vlahov D
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S1-2. PubMed ID: 21317588
    [No Abstract]   [Full Text] [Related]  

  • 10. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.
    Korthuis PT; Fiellin DA; Fu R; Lum PJ; Altice FL; Sohler N; Tozzi MJ; Asch SM; Botsko M; Fishl M; Flanigan TP; Boverman J; McCarty D;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S83-90. PubMed ID: 21317600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
    Roncero C; Domínguez-Hernández R; Díaz T; Fernández JM; Forcada R; Martínez JM; Seijo P; Terán A; Oyagüez I
    Adicciones; 2015 Sep; 27(3):179-89. PubMed ID: 26437312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial.
    Lucas GM; Chaudhry A; Hsu J; Woodson T; Lau B; Olsen Y; Keruly JC; Fiellin DA; Finkelstein R; Barditch-Crovo P; Cook K; Moore RD
    Ann Intern Med; 2010 Jun; 152(11):704-11. PubMed ID: 20513828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
    Soper R; Appajosyula S; Deximo C
    Adv Ther; 2018 Apr; 35(4):457-466. PubMed ID: 29623562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.
    Fiellin DA; Weiss L; Botsko M; Egan JE; Altice FL; Bazerman LB; Chaudhry A; Cunningham CO; Gourevitch MN; Lum PJ; Sullivan LE; Schottenfeld RS; O'Connor PG;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(0 1):S33-8. PubMed ID: 21317592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care.
    Egan JE; Netherland J; Gass J; Finkelstein R; Weiss L;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S46-53. PubMed ID: 21317594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.
    Barocas JA; Morgan JR; Fiellin DA; Schackman BR; Eftekhari Yazdi G; Stein MD; Freedberg KA; Linas BP
    Int J Drug Policy; 2019 Oct; 72():160-168. PubMed ID: 31085063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.
    Murphy SM; McCollister KE; Leff JA; Yang X; Jeng PJ; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
    Ann Intern Med; 2019 Jan; 170(2):90-98. PubMed ID: 30557443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial strategies for integrating buprenorphine into HIV care settings in the United States.
    Sullivan LE; Bruce RD; Haltiwanger D; Lucas GM; Eldred L; Finkelstein R; Fiellin DA
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S191-6. PubMed ID: 17109306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics.
    Korthuis PT; Tozzi MJ; Nandi V; Fiellin DA; Weiss L; Egan JE; Botsko M; Acosta A; Gourevitch MN; Hersh D; Hsu J; Boverman J; Altice FL;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S39-45. PubMed ID: 21317593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients.
    Edelman EJ; Chantarat T; Caffrey S; Chaudhry A; O'Connor PG; Weiss L; Fiellin DA; Fiellin LE
    Drug Alcohol Depend; 2014 Jun; 139():79-85. PubMed ID: 24726429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.